Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

National Cancer Institute, Bethesda, MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Bethesda, MD
Treatments:ChemotherapyHospital:National Cancer Institute
Drugs:Journal:Link
Date:May 2011

Description:

Patients:
This phase II study involved 40 patients with recurrent glioblastoma who had received prior treatment. The median patient age was 55 years and 75% were male.

Treatment:
Patients were treated with the chemotherapy agent romidepsin, which interferes with cancer cell DNA replication.

Toxicities:
The most severe reported adverse events were of grade 4 and included fatigue and thrombosis. Also reported were grade 3 neutropenia, lymphopenia, and thrombocytopenia.

Results:
The reported median overall survival was 7.8 months.

Correspondence: Dr. Howard Fine; email: [email protected]



Back